Trial Profile
A Randomized Phase III Study of Trastuzumab (Herceptin) in Combination With Either Vinorelbine (Navelbine), or Taxane-Based Chemotherapy in Patients With HER2 Overexpressing Metastatic Breast Cancer.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 18 Jul 2023
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Paclitaxel (Primary) ; Trastuzumab (Primary) ; Vinorelbine (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms TRAVIOTA
- 22 Jan 2008 The expected completion date for this trial is now .
- 21 Jul 2006 Status change
- 27 Nov 2005 New trial record.